Innovative Transseptal Access System Is First and Only to Feature Integrated Dilator and Needle to Reduce Exchanges
June 27, 2022 06:00 ET | Source: Acutus Medical, Inc.
...
CARLSBAD, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the commercial launch of an expanded suite of left-heart access products to now include the AcQCross™ Qx system for use with the TruSeal (TM) and FXD(TM) delivery system for the Watchman™ LAAC Device.
Gaining access to the left atrium requires physicians to cross the septum, a multi-step process that often involves the exchange of wires and needles while trying to achieve the proper angle and location on the septum. AcQCross is the first and only transseptal system engineered with an integrated needle and dilator to reduce these exchanges. US Left-atrial appendage closure procedures are expected to total over 50,000 in 2022, according to the Millennium Research Group. With this clearance, Acutus now offers sheath-compatible transseptal access devices that cover 409,000 electrophysiology and structural heart procedures in the US.
“Crossing the septum at the proper location is important when doing any left-sided heart procedure, but it can be especially critical to the success of delivering Watchman to the left atrial appendage,” said Dr. Tom Waggoner, DO, FACC, FSCAI, FSVM, RPVI, Director, Structural Heart Program and Cardiovascular Research, Tucson Medical Center, Tucson, Arizona. “With AcQCross, I can easily reposition without withdrawing or exchanging needles or wires, so its new compatibility with Watchman has made my procedures much safer for my patients and far more efficient for me and my team.”
AcQCross features an array of catheters that are length-, diameter- and tip-matched and designed to lock into the hub of market-leading sheaths used in the vast majority of left-heart procedures, including delivery of the Watchman. With the expanded product offering, physicians can utilize AcQCross with their preferred sheaths during virtually any left-heart access procedure.
“The AcQCross system provides interventional cardiologists and electrophysiologists with unique benefits of broad compatibility with market-leading access sheaths while also enhancing procedure versatility and workflow,” said David Roman, interim Chief Executive Officer and Chief Financial Officer, Acutus Medical. “The expanded AcQCross product line allows us to bring this innovative technology to a wider range of procedure categories that should drive sustained growth in this portfolio.”
AcQCross and its entire line of catheters are commercially available in the United States. For more information, visit www.acutusmedical.com/us/.
About Acutus Medical
Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.
Sale of Left-Heart Access Portfolio to Medtronic
On April 27, 2022, Acutus announced a definitive agreement to sell its left-heart access portfolio to Medtronic. Under the terms of the agreement, Medtronic will make an upfront cash payment to Acutus of $50 million upon the initial closing of the transaction, subject to the satisfaction of customary closing conditions, including expiration or early termination of all applicable waiting periods (and any extensions thereof) under applicable antitrust laws, and the closing of the Company’s debt refinancing, as well as contingent consideration payments over time based on the achievement of certain milestones and future sales.
Recent AFIB News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:12:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 09:00:32 PM
- Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 08:56:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:06:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:06:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:08:24 PM
- Acutus Medical Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 08:01:00 PM
- Acutus Medical Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:20:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:33:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:12:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:06:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 09:10:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 09:10:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:05:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:03:25 PM
- Acutus Medical to Cancel Third Quarter 2023 Conference Call • GlobeNewswire Inc. • 11/10/2023 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:06:34 PM
- Acutus Medical Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/08/2023 09:01:00 PM
- Acutus Medical Announces Strategic Realignment of Resources and Corporate Restructuring • GlobeNewswire Inc. • 11/08/2023 09:00:00 PM
- Acutus Medical to Announce Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/02/2023 08:13:07 PM
- Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 11/02/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 12:56:26 AM
- Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 10/02/2023 08:05:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM